RT Journal Article
T1 Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu
A1 García, María José
A1 Rivero, Montserrat
A1 Miranda Bautista, José
A1 Bastón-Rey, Iria
A1 Mesonero, Francisco
A1 Leo Carnerero, Eduardo
A1 Casas Deza, Diego
A1 Cagigas Fernández, Carmen
A1 Martín Cardona, Albert
A1 El Hajra, Ismael
A1 Hernández Aretxabaleta, Nerea
A1 Pérez Martínez, Isabel
A1 Fuentes Valenzuela, Esteban
A1 Jiménez, Nuria
A1 Rubín de Célix, Cristina
A1 Gutiérrez, Ana
A1 Suárez Ferrer, Cristina
A1 Huguet, José María
A1 Fernández Clotet, Agnes
A1 González Vivó, María
A1 Del Val, Blanca
A1 Castro Poceiro, Jesús
A1 Melcarne, Luigi
A1 Dueñas, Carmen
A1 Izquierdo, Marta
A1 Monfort, David
A1 Bouhmidi, Abdel
A1 Ramírez De la Piscina, Patricia
A1 Romero, Eva
A1 Molina, Gema
A1 Zorrilla, Jaime
A1 Calvino Suárez, Cristina
A1 Sánchez, Eugenia
A1 Nuñez, Andrea
A1 Sierra, Olivia
A1 Castro, Beatriz
A1 Zabana, Yamile
A1 González Partida, Irene
A1 De la Maza, Saioa
A1 Castaño, Andrés
A1 Nájera Muñoz, Rodrigo
A1 Sánchez Guillén, Luis
A1 Riat Castro, Micaela
A1 Rueda, José Luis
A1 Benítez, José Manuel
A1 Delgado Guillena, Pedro
A1 Tardillo, Carlos
A1 Peña, Elena
A1 Frago Larramona, Santiago
A1 Rodríguez Grau, María Carmen
A1 Plaza, Rocío
A1 Pérez Galindo, Pablo
A1 Martínez Cadilla, Jesús
A1 Menchén Viso, Luis Alberto
A1 Barreiro De Acosta, Manuel
A1 Sánchez Aldehuelo, Rubén
A1 De la Cruz, María Dolores
A1 Lamuela, Luis Javier
A1 Marín Jiménez, Ignacio
A1 Nieto García, Laura
A1 López San Román, Antonio
A1 Herrera, José Manuel
A1 Chaparro, María
A1 Gisbert, Javier P.
AB Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered “exposed”. The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2–2.0), urgent surgery (OR: 1.6; 95% CI: 1.2–2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1–1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3–2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97–1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03–2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.
PB MPDI
SN 2077-0383
YR 2021
FD 2021-09-26
LK https://hdl.handle.net/20.500.14352/4797
UL https://hdl.handle.net/20.500.14352/4797
LA eng
NO Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU)
DS Docta Complutense
RD 13 abr 2025